the aid library

LIST OPTIONS

Filter

11309

Sort by:

Direction:

Download (170)

View PDF (149)

Preparedness and Resilience for Emerging Threats Module 1: Planning for respiratory pathogen pandemics

World Health Organization WHO (2024) C_WHO

Through technical consultations with countries and partners, WHO has led the development of Preparedness and Resilience for Emerging Threats Module 1: Planning for respiratory pathogen pandemics. Version 1.0. The Module, currently available as an advanced draft, builds on previous pandemic lessons a... more

Download (199)

View PDF (277)

Cleaning and disinfection of environmental surfaces in the context of COVID-19
recommended

World Health Organisation (2020) C_WHO

The purpose of this document is to provide guidance on the cleaning and disinfection of environmental surfaces in the context of COVID-19. This guidance is intended for health care professionals, public health professionals and health authorities that are developing and implementing policies and sta... more

Download (803)

View PDF (1715)

Manual for the Development and Assessment of National Viral Hepatitis Plans

Joe Schofield, Sarah Hess, Bandana Malhotra et al. World Health Organization (WHO) (2015)

A Provisional Document. The purpose of this manual is to provide guidance to public health professionals tasked with managing a response to viral hepatitis. As every country’s needs are different with respect to its epidemiology and the current level of response, people would use this manual in di... more

Download (280)

View PDF (375)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (157)

View PDF (196)

Standard operating procedures for surveillance of meningitis preparedness and response to epidemics in Africa

World Health Organization WHO (2018) C_WHO

Epidemic meningitis is a major public health challenge in the African 'meningitis belt', an area that extends from Senegal to Ethiopia with an estimated total population of 500 million. Since 2002, the World Health Organization (WHO), in collaboration with its collaborating centres for meningitis, h... more

Download (197)

View PDF (276)

Fit for women? Safe and decent PPE for women health and care workers

Women for Global Health WGH (2021) CC

One of the many gender inequities in the health and care workforce that COVID-19 has exposed is around the fit and design of Personal Protective Equipment (PPE). The rapid onset and scale of COVID-19 led to shortages of PPE in most countries, causing preventable infection and mortality among healthc... more

Download (962)

View PDF (1940)

Tool to assess the association between injections and infections

World Health Organization (2001)

Download (1443)

View PDF (2603)

WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings
recommended

World Health Organization (2016) C_WHO

Download (179)

View PDF (228)

Climate change and communicable diseases: a manual for health workers

World Health Organization. Regional Office for Europe (2011) C_WHO

There is a broad consensus nowadays that the Earth is warming up as a result of greenhouse gas emissions caused by anthropogenic activities. It is also clear that current trends in the fields of energy, development and population growth will lead to continuous and ever more dramatic climate change. ... more

Download (1309)

View PDF (3214)

WHO/UNICEF Strategic Plan for Polio Outbreak Response in the Middle East

The Polio Global Eradication Initiative WHO (2013)

THE SYRIAN ARAB REPUBLIC, IRAQ, JORDAN, LEBANON, TURKEY, WEST BANK AND GAZA STRIP, EGYPT

Download (65)

View PDF (475)

E-learning Plattform Nigeria Center for Disease Control

Nigeria Center for Disease Control (2021) CC

Here you can find the various e-learning courses

Download (242)

View PDF (405)

Joint tuberculosis control programme review mission to the Republic of Moldova

Dr. M. Kavtaradze, Dr. S. Ciobanu World Health Organization Europe (2012) C_WHO

Download (295)

View PDF (401)

Role in Prevention & Controle of Non-communicable Diseases (NCDs)

Ministry of Health & Family Welfare, India (2009) CC

Reading Material for ASHA no.8

Download (1326)

View PDF (2822)

Guidelines For Laboratory And Field Testing Of Long-Lasting Insecticidal Mosquito Nets

World Health Organization (2005) C_WHO

Download (57)

View PDF (664)

Prévention et contrôle des infections (PCI) appliqués au nouveau coronavirus (COVID-19)

Organisation Mondiale de la Santé OMS (2020) C_WHO

Ce cours fournit des informations sur ce que les établissements devraient faire afin d'être prêts à réagir face à un cas de virus respiratoire émergent tel que le nouveau coronavirus, sur la manière d'identifier un cas lorsqu'il se présente, et sur la façon correcte de mettre en place des ... more